Holen Sie sich die Stockscreener-App
16.21
1.69%
0.27
Handel nachbörslich:
16.21
Schlusskurs vom Vortag:
$15.94
Offen:
$15.94
24-Stunden-Volumen:
1.85M
Relative Volume:
1.08
Marktkapitalisierung:
$1.94B
Einnahmen:
$59.61M
Nettoeinkommen (Verlust:
$-262.14M
KGV:
-4.1352
EPS:
-3.92
Netto-Cashflow:
$-247.49M
1W Leistung:
+4.65%
1M Leistung:
+11.64%
6M Leistung:
+20.97%
1J Leistung:
+54.97%
1-Tages-Spanne:
$15.93
$16.55
1-Wochen-Bereich:
$15.10
$16.55
52-Wochen-Spanne:
$8.03
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Firmenname
Arcutis Biotherapeutics Inc
Sektor
Branche
Telefon
805-418-5006
Adresse
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Vergleichen Sie ARQT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
16.21 | 1.84B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Eingeleitet | Goldman | Neutral |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-10-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-09-07 | Eingeleitet | Needham | Buy |
| 2022-03-17 | Eingeleitet | Goldman | Buy |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-05-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Hochstufung | Goldman | Neutral → Buy |
| 2020-10-08 | Eingeleitet | Truist | Buy |
| 2020-02-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Eingeleitet | Cowen | Outperform |
| 2020-02-25 | Eingeleitet | Goldman | Neutral |
| 2020-02-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Arcutis submits sNDA for roflumilast cream 0.3% for treatment of psoriasis in children 2-5 years - Contemporary Pediatrics
PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight - GlobeNewswire Inc.
Arcutis Seeks Expanded Indication for Zoryve - MarketScreener
Arcutis Submits sNDA for Roflumilast Cream 0.3% for Psoriasis in Children Aged 2-5 Years - HCP Live
Arcutis seeks FDA approval for psoriasis cream for young children - Investing.com
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 - The Manila Times
Arcutis Biotherapeutics Submits Application for ZORYVE Cream as First Topical Treatment for Plaque Psoriasis in Children Ages 2 and Up - Quiver Quantitative
First-Ever PDE4 Inhibitor for Toddlers: Arcutis' ZORYVE Aims to Transform Psoriasis Treatment Ages 2-5 - Stock Titan
Developing predictive dashboards with Arcutis Biotherapeutics Inc. dataOil Prices & Weekly Watchlist of Top Performers - Newser
Relative strength of Arcutis Biotherapeutics Inc. in sector analysisQuarterly Market Review & Momentum Based Trading Signals - Newser
Detecting support and resistance levels for Arcutis Biotherapeutics Inc.July 2025 PostEarnings & Weekly Chart Analysis and Guides - Newser
Chart based analysis of Arcutis Biotherapeutics Inc. trendsJuly 2025 Recap & High Accuracy Investment Entry Signals - Newser
Former Arcutis CTO with 52 US Patents Joins Palvella Therapeutics to Expand Rare Skin Disease Platform - Stock Titan
Ranking Arcutis Biotherapeutics Inc. among high performing stocks via toolsTrade Signal Summary & Daily Profit Maximizing Tips - Newser
Using Bollinger Bands to evaluate Arcutis Biotherapeutics Inc.July 2025 Big Picture & Step-by-Step Swing Trade Plans - Newser
Long term hold vs stop loss in Arcutis Biotherapeutics Inc.Quarterly Portfolio Summary & Target Return Focused Picks - Newser
Is Arcutis Biotherapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Fed Impact & Growth Focused Entry Point Reports - Newser
What high frequency data says about Arcutis Biotherapeutics Inc.Trade Risk Summary & Stepwise Entry and Exit Trade Signals - Newser
Using Ichimoku Cloud for Arcutis Biotherapeutics Inc. technicalsJuly 2025 Recap & High Accuracy Buy Signal Tips - Newser
Chart overlay techniques for tracking Arcutis Biotherapeutics Inc.2025 EndofYear Setup & Consistent Income Trade Recommendations - Newser
What’s the outlook for Arcutis Biotherapeutics Inc.’s sectorMarket Volume Summary & Daily Profit Maximizing Trade Tips - khodrobank.com
What is Arcutis Biotherapeutics Inc. s 5 year growth outlookQuarterly Risk Review & Free Low Drawdown Momentum Trade Ideas - khodrobank.com
Is Arcutis Biotherapeutics Inc. stock a smart retirement pick2025 Investor Takeaways & Real-Time Volume Spike Alerts - khodrobank.com
HCPLive 5 Stories in Under 5: Week of 08/24 - HCP Live
Can Arcutis Biotherapeutics Inc. sustain earnings growthMarket Weekly Review & Precise Entry and Exit Recommendations - khodrobank.com
Will Arcutis Biotherapeutics Inc. benefit from current market trendsEarnings Summary Report & Growth Oriented Trading Recommendations - khodrobank.com
Is Arcutis Biotherapeutics Inc. backed by strong institutional buyingJuly 2025 Retail & Reliable Entry Point Trade Alerts - khodrobank.com
What are analysts’ price targets for Arcutis Biotherapeutics Inc.July 2025 Retail & Reliable Entry Point Trade Alerts - khodrobank.com
Can Arcutis Biotherapeutics Inc. stock double in the next yearMarket Sentiment Report & Technical Entry and Exit Alerts - khodrobank.com
Is Arcutis Biotherapeutics Inc. stock showing strong momentum2025 Performance Recap & Low Drawdown Momentum Trade Ideas - khodrobank.com
Is Arcutis Biotherapeutics Inc. forming a bullish divergence2025 Buyback Activity & Proven Capital Preservation Methods - khodrobank.com
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect? - sharewise.com
What’s the beta of Arcutis Biotherapeutics Inc. stockWeekly Investment Recap & AI Powered Market Entry Ideas - khodrobank.com
Understanding Arcutis Biotherapeutics Inc.’s price movementChart Signals & Community Trade Idea Sharing Platform - Newser
Trend Reversal Possible in Arcutis Biotherapeutics Inc. Charts Indicate getLinesFromResByArray error: size == 0 - thegnnews.com
Combining machine learning predictions for Arcutis Biotherapeutics Inc.2025 AllTime Highs & Low Drawdown Investment Strategies - Newser
Can you recover from losses in Arcutis Biotherapeutics Inc.Quarterly Performance Summary & Community Trade Idea Sharing Platform - Newser
Will Arcutis Biotherapeutics Inc. rebound enough to break evenMarket Rally & Risk Managed Investment Strategies - Newser
Is Arcutis Biotherapeutics Inc. still worth holding after the dipPortfolio Update Report & Breakout Confirmation Trade Signals - Newser
Arcutis Biotherapeutics Inc. stock retracement – recovery analysis2025 EndofYear Setup & High Conviction Trade Alerts - Newser
Published on: 2025-08-31 13:24:11 - Newser
Will Arcutis Biotherapeutics Inc. continue its uptrendSwing Trade & Proven Capital Preservation Tips - Newser
Analysts Spot Bullish Divergence in Arcutis Biotherapeutics Inc. getLinesFromResByArray error: size == 0 - 클래시안
What momentum shifts mean for Arcutis Biotherapeutics Inc.2025 Year in Review & Verified Chart Pattern Signals - Newser
Finanzdaten der Arcutis Biotherapeutics Inc-Aktie (ARQT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arcutis Biotherapeutics Inc-Aktie (ARQT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Burnett Patrick | See Remarks |
Aug 21 '25 |
Sale |
15.57 |
2,438 |
37,969 |
104,811 |
| Burnett Patrick | See Remarks |
Aug 19 '25 |
Sale |
16.16 |
1,750 |
28,281 |
107,249 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):